These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 27528374)

  • 41. Incretin-based medications for type 2 diabetes: an overview of reviews.
    Gamble JM; Clarke A; Myers KJ; Agnew MD; Hatch K; Snow MM; Davis EM
    Diabetes Obes Metab; 2015 Jul; 17(7):649-58. PubMed ID: 25772666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
    Yang M; Wang L; Gu L; Yuan W
    J Diabetes; 2017 Dec; 9(12):1107-1117. PubMed ID: 28266136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
    Li R; Wang R; Li H; Sun S; Zou M; Cheng G
    Diabetes Metab Res Rev; 2016 Sep; 32(6):460-9. PubMed ID: 26433213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
    Chen Y; Men K; Li XF; Li J; Liu M; Fan ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3502-3514. PubMed ID: 29917205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M; Liu Y; Jin J; He Q
    Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis.
    Chou CY; Chang YT; Yang JL; Wang JY; Lee TE; Wang RY; Hung CC
    Sci Rep; 2017 Nov; 7(1):15795. PubMed ID: 29150631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials.
    Dos Santos Borges R; de Oliveira Almeida G; Alves VFC; Nienkotter TF; Bertoli ED; Simões E Silva AC
    J Nephrol; 2024 May; 37(4):881-896. PubMed ID: 38141092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
    Zhang DP; Xu L; Wang LF; Wang HJ; Jiang F
    Cardiovasc Diabetol; 2020 Jan; 19(1):10. PubMed ID: 31969144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.
    Slinin Y; Ishani A; Rector T; Fitzgerald P; MacDonald R; Tacklind J; Rutks I; Wilt TJ
    Am J Kidney Dis; 2012 Nov; 60(5):747-69. PubMed ID: 22999165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Luo Y; Lu K; Liu G; Wang J; Laurent I; Zhou X
    Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Gao L; Yu S; Cipriani A; Wu S; Huang Y; Zhang Z; Yang J; Sun Y; Yang Z; Chai S; Zhang Y; Ji L; Zhan S; Sun F
    Aging Dis; 2019 Dec; 10(6):1311-1319. PubMed ID: 31788342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
    O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V
    Diabetes Obes Metab; 2021 Mar; 23(3):763-773. PubMed ID: 33269512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
    Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
    Muskiet MH; Smits MM; Morsink LM; Diamant M
    Nat Rev Nephrol; 2014 Feb; 10(2):88-103. PubMed ID: 24375052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.